Independent venture capital firm Truffle Capital has appointed former VEXIM CEO Vincent Gardès as a senior partner in the firm’s BioMedTech team.
Under the leadership of Philippe Pouletty, MD, the team also includes Alain Chevallier and Antoine Pau.
Gardès will have responsibility for generating new investments in the field of medical devices for Truffle Capital’s new BioMedTech fund and will actively support Truffle portfolio companies.
“My work relationship with Truffle Capital goes back many years, to the days when I was hired as CEO of VEXIM, a company founded by Truffle Capital and acquired by Stryker Corporation in April 2018 for EUR183 million,” says Gardès. “Having recently left VEXIM, I am now delighted to be on the other side of the fence and start building, with our BioMedTech Fund and other Truffle Funds, new companies dedicated to revolutionising interventional mini-invasive medicine.”
Pouletty, Chevallier, and Pau add: “We are very happy to welcome Vincent Gardès and look forward to benefitting from his global expertise in interventional medicine and medical devices. At Truffle Capital, we pride ourselves on being both entrepreneurs and investors, and source radical innovations in the top universities in the US and Europe to create, in France, future global market leaders. What gives Truffle Capital and our BioMedTech team strength and added-value for our portfolio companies are our complementary skills.”
Truffle Capital has already created and financed 3 companies with its new BioMedTech Fund over the last few months: HoliStick Medical, ArteDrone and Nanosive. In total, a dozen BioMedTech companies could be financed by Truffle Capital with its new Fund and other co-investment funds.
